2021
575 Application of Pharmacogenomic Guided Immunosuppression Dosing in Allogeneic Hematopoietic Stem Cell Transplant (HSCT)
Perreault S, Schiffer M, Gowda L, Foss F, Isufi I, Seropian S. 575 Application of Pharmacogenomic Guided Immunosuppression Dosing in Allogeneic Hematopoietic Stem Cell Transplant (HSCT). Transplantation And Cellular Therapy 2021, 27: s461. DOI: 10.1016/s2666-6367(21)00600-x.Peer-Reviewed Original Research
2020
Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas
Lee M, Schiffer M, Isufi I, Huntington S, Xu M, Seropian S, Gowda L, Kothari S, Girardi M, Foss F. Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas. Blood 2020, 136: 21-22. DOI: 10.1182/blood-2020-139790.Peer-Reviewed Original ResearchT-cell lymphomaAggressive T-cell lymphomaWeekly dosing scheduleMycosis fungoides/Sezary syndromeMF/SSWeekly dosingCell lymphomaDosing schedulesBrentuximab vedotinSezary syndromeGamma-delta T-cell lymphomaWeekly scheduleNK-T cell lymphomaAngioimmunoblastic T-cell lymphomaPeripheral T-cell lymphomaAnaplastic large cell lymphomaCancer response rateIncidence of neuropathyWeekly x 3Prospective clinical trialsStem cell transplantAdult T-cell leukemiaLarge cell lymphomaT-cell leukemiaDose weekly
2018
Hepatosplenic T-Cell Lymphomas
Gowda L, Foss F. Hepatosplenic T-Cell Lymphomas. Cancer Treatment And Research 2018, 176: 185-193. PMID: 30596219, DOI: 10.1007/978-3-319-99716-2_9.Peer-Reviewed Original ResearchConceptsHepatosplenic T-cell lymphomaT-cell lymphomaPeripheral T-cell lymphomaHematopoietic stem cell transplantExtranodal peripheral T-cell lymphomaLimited salvage optionsYear of diagnosisAggressive disease courseBone marrow involvementStem cell transplantEligible patientsMarrow involvementPerformance statusPost chemotherapyDisease courseImmune dysregulationProlong remissionSalvage optionCell transplantClinical manifestationsTherapeutic armamentariumLethal outcomeAggressive phenotypeFourth decadeModest response
2015
The use of basiliximab–infliximab combination for the treatment of severe gastrointestinal acute GvHD
Nadeau M, Perreault S, Seropian S, Foss F, Isufi I, Cooper DL. The use of basiliximab–infliximab combination for the treatment of severe gastrointestinal acute GvHD. Bone Marrow Transplantation 2015, 51: 273-276. PMID: 26479982, DOI: 10.1038/bmt.2015.247.Peer-Reviewed Original ResearchConceptsGastrointestinal acute GVHDAcute GVHDGrade IIIAllogeneic stem cell transplantCombination of basiliximabSevere GI GvHDSevere grade IIISteroid-refractory diseaseLong-term survivorsStem cell transplantOverall response rateCurrent retrospective studyChronic GVHDGI GVHDSalvage therapySteroid therapyPrimary diseaseCell transplantMedian timeSignificant morbidityPoor outcomeRetrospective studyGVHDMost deathsNew agents
2010
Current and Emerging Treatment Strategies for Cutaneous T-cell Lymphoma
Lansigan F, Foss FM. Current and Emerging Treatment Strategies for Cutaneous T-cell Lymphoma. Drugs 2010, 70: 273-286. PMID: 20166766, DOI: 10.2165/11532190-000000000-00000.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaMalignant T cellsTreatment strategiesT cellsManagement of CTCLPredictable adverse effectsRapid disease controlConservative treatment strategyFront-line therapyEarly-stage diseaseIndolent clinical courseMature T-cell lymphomasStem cell transplantInterleukin-2 receptorHistone deacetylase inhibitorsSystemic chemotherapyExtracorporeal photopheresisInitial managementSézary syndromeClinical courseCurative therapyBiological therapyCell transplantMycosis fungoides